Alcon & AMO Development Asked Federal Circuit to Re-Review U.S. Patent No. 8,500,724 Prior to Settlement Pact
AMO Development, LLC, contends a high-energy ablating ultraviolet laser can’t correct internal eye problems because it would first destroy corneal tissue because “laser pulses are highly absorbed in whatever tissue they first encounter.” The U.S. Patent Trial and Appeal Board agreed in IPR2021-00856. Alcon Inc., Alcon Vision, LLC, Alcon Laboratories, Inc., and Alcon Research, LLC, diagree. In cross-appeals, the parties ask the U.S. Court for Appeals for the Federal Circuit to review the PTAB’s inter partes review decision. AMO Development, LLC, the Patent Owner, is represented by a team of lawyers at LATHAM & WATKINS LLP, and Alcon is…
More from UncategorizedMore posts in Uncategorized »
- Overexposure to UV During Pedicure Nail Treatment May Have Caused Cell Damage and Resultant Toe Amputation
- US Patent Issued 2023 – US 11602576 B1 “Air/gas compressor with viral/bacterial ultraviolet radiation filtration”
- WIPO Patent Application – 202347003307 “SYSTEM AND METHOD FOR DISINFECTING SURFACES OF ARTICLES TRANSPORTED ON A CONVEYOR SYSTEM”
- UV Exposure Risk During Gel Nail Polish Application and Drying – A New Study Report
- Costa Group Holdings Sustainability Report for 2022 Mentions Use of UV Filtration as Part of Water Recycling